<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Ovarian Res</journal-id><journal-id journal-id-type="iso-abbrev">J Ovarian Res</journal-id><journal-title-group><journal-title>Journal of Ovarian Research</journal-title></journal-title-group><issn pub-type="epub">1757-2215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30917839</article-id><article-id pub-id-type="pmc">6436212</article-id><article-id pub-id-type="publisher-id">504</article-id><article-id pub-id-type="doi">10.1186/s13048-019-0504-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Effects of hysterectomy with simultaneous bilateral salpingectomy on the subsequent pelvic mass</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Chao</surname><given-names>Xiaopei</given-names></name><address><email>xy7cxp@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wang</surname><given-names>Xiaoxia</given-names></name><address><email>xiaoxia_wang@sina.cn</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Xiao</surname><given-names>Yu</given-names></name><address><email>xiaoyu_pumch@163.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ji</surname><given-names>Mingliang</given-names></name><address><email>jimingliang@pumch.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5447-0946</contrib-id><name><surname>Wang</surname><given-names>Shu</given-names></name><address><phone>+86-136-7124-6680</phone><email>wangshu219@hotmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Shi</surname><given-names>Honghui</given-names></name><address><phone>+86-136-7124-6680</phone><email>honghui_s@sina.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fan</surname><given-names>Qingbo</given-names></name><address><email>qbfan@sohu.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhu</surname><given-names>Lan</given-names></name><address><phone>+86-136-7124-6680</phone><email>zhu_julie@vip.sina.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Leng</surname><given-names>Jinhua</given-names></name><address><email>jinhua_l@sina.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Dawei</given-names></name><address><email>dawei_s@sina.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lang</surname><given-names>Jinghe</given-names></name><address><email>langjh@hotmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9889 6335</institution-id><institution-id institution-id-type="GRID">grid.413106.1</institution-id><institution>Department of Obstetrics and Gynecology, </institution><institution>Peking Union Medical College Hospital, Peking Union Medical College &#x00026; Chinese Academy of Medical Science, </institution></institution-wrap>Shuaifuyuan No. 1, Dongcheng District, Beijing, 100730 China </aff><aff id="Aff2"><label>2</label>Department of Gynecology, Gansu Provincial Maternity and Child-care Hospital, Lanzhou City, Gansu Province People&#x02019;s Republic of China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9889 6335</institution-id><institution-id institution-id-type="GRID">grid.413106.1</institution-id><institution>Department of Pathology, </institution><institution>Peking Union Medical College Hospital, Peking Union Medical College &#x00026; Chinese Academy of Medical Science, </institution></institution-wrap>Beijing, 100730 China </aff></contrib-group><pub-date pub-type="epub"><day>27</day><month>3</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>27</day><month>3</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>12</volume><elocation-id>27</elocation-id><history><date date-type="received"><day>18</day><month>1</month><year>2019</year></date><date date-type="accepted"><day>19</day><month>3</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2019</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Objectives</title><p id="Par1">To analyze the clinicopathological characteristics of subsequent pelvic masses after hysterectomy for benign diseases, and to compare the masses following hysterectomy with or without simultaneous bilateral salpingectomy.</p></sec><sec><title>Methods</title><p id="Par2">This study retrospectively analyzed patients undergone reoperation for pelvic mass subsequently to previous hysterectomy for benign disease from January 2012 to December 2016 in Peking Union Medical College Hospital.</p></sec><sec><title>Results</title><p id="Par3">A total of 247 patients were enrolled in this study, of which 80.16% (<italic>n</italic>&#x02009;=&#x02009;198) received simple hysterectomy, and 5.67% (<italic>n</italic>&#x02009;=&#x02009;14) underwent hysterectomy with bilateral salpingectomy. The clinicopathological data of patients undergone simple hysterectomy or simultaneous bilateral salpingectomy was compared. In the former group, we found that 68.18% (<italic>n</italic>&#x02009;=&#x02009;135) of the pelvic massed were benign, and the remaining 31.82% (<italic>n</italic>&#x02009;=&#x02009;63) were malignant. In latter group, 57.10% (<italic>n</italic>&#x02009;=&#x02009;8) were benign (8%) and 42.90% (<italic>n</italic>&#x02009;=&#x02009;6) were malignant. Univariate analysis showed that the age of surgery for pelvic masses in patients undergoing hysterectomy with simultaneous bilateral salpingectomy was significantly younger than that in patients without salpingectomy (median, 44.5 vs 50&#x02009;years, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001), and the time interval between hysterectomy and onset of pelvic masses was also significantly shorter (median, 2 vs 5&#x02009;years, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001). And the probability of pelvic encapsulated effusion was significantly higher for the salpingectomy group. Multivariate analysis showed that there was no significant difference of the age of resection of pelvic mass, the time interval hysterectomy and pelvic mass onset, and the probability of pelvic encapsulated effusion between the two groups.</p></sec><sec><title>Conclusions</title><p id="Par4">The results showed that the incidence of secondary benign pelvic masses may be reduced when hysterectomy was performed with simultaneous bilateral salpingectomy. However, there was no statistical difference in the clinical characteristics and pathological types of pelvic masses between patients received hysterectomy with or without salpingectomy.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Hysterectomy</kwd><kwd>Salpingectomy</kwd><kwd>Pelvic mass</kwd><kwd>Diagnosis</kwd></kwd-group><funding-group><award-group><funding-source><institution>CAMS Youth Talent Award Project</institution></funding-source><award-id>2018RC320006</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Shu</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>CAMS Innovation Fund for Medical Sciences(CIFMS)</institution></funding-source><award-id>2016-I2M-1-002</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Shu</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Chinese Academy of Medical Sciences Initiative for Innovative Medicine</institution></funding-source><award-id>CAMS-2017-I2M-1-002</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Shu</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par7">Hysterectomy is the most common gynecological operation and is widely accepted as the final treatment of many common gynecological diseases. However, the risk of reoperation increased due to complications of hysterectomy, such as pelvic adhesion. The recurrence of pelvic mass after hysterectomy is the common reason for reoperation [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. It had been reported that simultaneous bilateral salpingectomy during hysterectomy may reduce the incidence of ovarian serous carcinoma and some benign pelvic diseases, thus reducing the risk of reoperation after hysterectomy [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>]. Simultaneous bilateral salpingectomy has been routinely carried out in many medical institutions at present. However, few studies have explained whether salpingectomy affects the time of pelvic mass onset, clinical characteristics and pathological types of pelvic masses after hysterectomy in patients who have been treated again for various pelvic masses.</p><p id="Par8">This study reviewed the medical records of patients received reoperation for pelvic masses following hysterectomy due to benign diseases, compared the clinical and pathological features in patients who underwent hysterectomy with or without bilateral salpingectomy, and analyzed the possible influence of simultaneous salpingectomy on the recurrence of pelvic masses.</p></sec><sec id="Sec2"><title>Methods and materials</title><sec id="Sec3"><title>Ethics</title><p id="Par9">This study was approved by the Ethics Committee of Peking Union Medical College Hospital (No. S-K331).</p></sec><sec id="Sec4"><title>Patients</title><p id="Par10">Identify patients who underwent surgery in Peking Union Medical College Hospital for pelvic mass after hysterectomy due to benign disease from January 2012 to December 2016 using ICD-9 disease code.</p><sec id="Sec5"><title>Inclusion criteria</title><p id="Par11">A history of hysterectomy due to gynecological benign disease was clearly identified, and patients who underwent reoperation for pelvic mass during the required time period were included.</p></sec><sec id="Sec6"><title>Exclusion criteria</title><p id="Par12">Patients who underwent surgery for pelvic mass but had no history of hysterectomy, had a uterine pathology of malignant tumors, or whose surgery of pelvic mass was not performed in the specified period were excluded from the study.</p><p id="Par13">Medical staff collected the medical records of enrolled patients in detail, including age of hysterectomy and the indications, age of the pelvic mass onset, time interval from the hysterectomy to the onset of pelvic mass, oviduct or ovary being resected or remained in previous surgery, main manifestations and imaging features at the time of pelvic mass onset, and pathological type of the pelvic mass. Patients were divided into two groups according to hysterectomy with or without bilateral salpingectomy, and the clinicopathological characteristics of two groups were compared and analyzed.</p></sec></sec></sec><sec id="Sec7"><title>Statistics</title><p id="Par14">The statistical analysis was performed using SPSS 23.0 (SPSS Inc., Chicago, IL, USA) in reference to whether the fallopian tubes were resected or not. Receiver Operating Characteristic (ROC) curve was constructed to define the optimal cutoff value for age of hysterectomy (&#x0003c;&#x02009;45&#x02009;years vs &#x02265;45&#x02009;years), age of the operation for pelvic mass (&#x0003c;&#x02009;52&#x02009;years vs &#x02265;52&#x02009;years), and time interval from the hysterectomy to the onset of pelvic mass (&#x0003c;&#x02009;5&#x02009;years vs &#x02265;5&#x02009;years) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Continuous variables were summarized with medians and interquartile ranges. Two groups were analyzed by independent t test, and multiple groups were analyzed by one-way ANOVA. The categorical variables were summarized with rates using Chi-square test or Fisher&#x02019;s exact test to analyze. Variables with <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 by univariate analysis were included in multivariate analysis, and logistic regression model was used for fitting with <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 considered statistical significance. All analysis was two-sided and significance level was set at <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Univariate analysis of clinical characteristics of pelvic masses following hysterectomy with or without simultaneous bilateral salpingectomy</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Hys N(%)</th><th>Hys&#x02009;+&#x02009;BS N(%)</th><th><italic>P</italic> value</th></tr></thead><tbody><tr><td>Total number of cases</td><td>198</td><td>14</td><td/></tr><tr><td>Age at hysterectomy (median[IQR], years)</td><td>43 [40,47]</td><td>42 [36,44]</td><td>0.143</td></tr><tr><td colspan="4">&#x02003;Group of age at hysterectomy</td></tr><tr><td>&#x02003;&#x02003;&#x0003c;&#x02009;45</td><td>116 (58.6)</td><td>11 (78.6)</td><td>0.168</td></tr><tr><td>&#x02003;&#x02003;&#x02265;45</td><td>82 (41.4)</td><td>3 (21.4)</td><td/></tr><tr><td colspan="4">Etiology of hysterectomy</td></tr><tr><td colspan="4">&#x02003;Endometriosis/adenomyosis</td></tr><tr><td>&#x02003;&#x02003;No</td><td>150 (75.8)</td><td>4 (28.6)</td><td>&#x0003c;&#x02009;0.0001</td></tr><tr><td>&#x02003;&#x02003;Yes</td><td>48 (24.2)</td><td>10 (71.4)</td><td/></tr><tr><td colspan="4">&#x02003;Uterine leiomyoma</td></tr><tr><td>&#x02003;&#x02003;No</td><td>64 (32.3)</td><td>9 (64.3)</td><td>0.020</td></tr><tr><td>&#x02003;&#x02003;Yes</td><td>134 (67.7)</td><td>5 (35.7)</td><td/></tr><tr><td colspan="4">&#x02003;Postpartum massive hemorrhage</td></tr><tr><td>&#x02003;&#x02003;No</td><td>195 (98.5)</td><td>14 (100)</td><td>1.0</td></tr><tr><td>&#x02003;&#x02003;Yes</td><td>3 (1.5)</td><td>0 (0)</td><td/></tr><tr><td colspan="4">&#x02003;Cervical intraepithelial neoplasia</td></tr><tr><td>&#x02003;&#x02003;No</td><td>186 (93.9)</td><td>14 (100)</td><td>1.0</td></tr><tr><td>&#x02003;&#x02003;Yes</td><td>12 (6.1)</td><td>0 (0)</td><td/></tr><tr><td colspan="4">&#x02003;Endometrial intraepithelial neoplasia</td></tr><tr><td>&#x02003;&#x02003;No</td><td>194 (98.0)</td><td>14 (100)</td><td>1.0</td></tr><tr><td>&#x02003;&#x02003;Yes</td><td>4 (2.0)</td><td>0 (0)</td><td/></tr><tr><td colspan="4">Manifestation for medical consultation</td></tr><tr><td colspan="4">&#x02003;Physical examination findings</td></tr><tr><td>&#x02003;&#x02003;No</td><td>96 (48.5)</td><td>8 (57.1)</td><td>0.531</td></tr><tr><td>&#x02003;&#x02003;Yes</td><td>102 (51.5)</td><td>6 (42.9)</td><td/></tr><tr><td colspan="4">&#x02003;Abdominal distension and anorexia</td></tr><tr><td>&#x02003;&#x02003;No</td><td>163 (82.3)</td><td>13 (92.9)</td><td>0.473</td></tr><tr><td>&#x02003;&#x02003;Yes</td><td>35 (17.7)</td><td>1 (7.1)</td><td/></tr><tr><td colspan="4">&#x02003;Abnormal defecation</td></tr><tr><td>&#x02003;&#x02003;No</td><td>190 (96.0)</td><td>13 (92.9)</td><td>0.466</td></tr><tr><td>&#x02003;&#x02003;Yes</td><td>8 (4.0)</td><td>1 (7.1)</td><td/></tr><tr><td colspan="4">&#x02003;Abdominal pain</td></tr><tr><td>&#x02003;&#x02003;No</td><td>151 (76.3)</td><td>9 (64.3)</td><td>0.339</td></tr><tr><td>&#x02003;&#x02003;Yes</td><td>47 (23.7)</td><td>5 (35.7)</td><td/></tr><tr><td colspan="4">&#x02003;Micturition</td></tr><tr><td>&#x02003;&#x02003;No</td><td>187 (94.4)</td><td>14 (100)</td><td>1.0</td></tr><tr><td>&#x02003;&#x02003;Yes</td><td>11 (5.6)</td><td>0 (0)</td><td/></tr><tr><td colspan="4">&#x02003;Lower limb pain</td></tr><tr><td>&#x02003;&#x02003;No</td><td>196 (99.0)</td><td>14 (100)</td><td>1.0</td></tr><tr><td>&#x02003;&#x02003;Yes</td><td>2 (1.0)</td><td>0 (0)</td><td/></tr><tr><td colspan="4">&#x02003;Vaginal flow or bleeding</td></tr><tr><td>&#x02003;&#x02003;No</td><td>194 (98.0)</td><td>14 (100)</td><td>1.0</td></tr><tr><td>&#x02003;&#x02003;Yes</td><td>4 (2.0)</td><td>0 (0)</td><td/></tr><tr><td colspan="4">Total/Subtotal hysterectomy</td></tr><tr><td>&#x02003;Total</td><td>166 (83.8)</td><td>14 (100)</td><td>0.135</td></tr><tr><td>&#x02003;Subtotal</td><td>32 (16.2)</td><td>0 (0)</td><td/></tr><tr><td>Age of surgery for pelvic mass (median[IQR])</td><td>50 [47,56]</td><td>44.5[41, 49]</td><td>&#x0003c;&#x02009;0.0001</td></tr><tr><td colspan="4">Age group</td></tr><tr><td>&#x02003;&#x0003c;&#x02009;52</td><td>114 (57.58)</td><td>14 (100)</td><td>0.001</td></tr><tr><td>&#x02003;&#x02265;52</td><td>84 (42.42)</td><td>0 (0)</td><td/></tr><tr><td>The time interval from hysterectomy to the pelvic mass onset (median[IQR])</td><td>5 [2,10]</td><td>2 [1,4]</td><td>&#x0003c;&#x02009;0.0001</td></tr><tr><td colspan="4">&#x02003;Time group</td></tr><tr><td>&#x02003;&#x02003;&#x02009;&#x0003c;&#x02009;5</td><td>89 (44.95)</td><td>11 (78.6)</td><td>0.024</td></tr><tr><td>&#x02003;&#x02003;&#x02009;&#x02265;&#x02009;5</td><td>109 (55.05)</td><td>3 (21.4)</td><td/></tr><tr><td>The time interval from hysterectomy to the pelvic benign mass onset (median[IQR])</td><td>4.0[2, 9.25]<break/>(<italic>n</italic>&#x02009;=&#x02009;134)</td><td>1.5[0.7,3.0]<break/>(n&#x02009;=&#x02009;8)</td><td>&#x0003c;&#x02009;0.0001</td></tr><tr><td>The time interval from hysterectomy to the pelvic malignant mass onset (median[IQR])</td><td>7 [3,10.75]<break/>(<italic>n</italic>&#x02009;=&#x02009;64)</td><td>4.5 [0.93, 8.25]<break/>(<italic>n</italic>&#x02009;=&#x02009;6)</td><td>0.223</td></tr></tbody></table><table-wrap-foot><p><italic>Abbreviations</italic>: <italic>BS</italic> bilateral salpingectomy, <italic>Hys</italic> Hysterectomy, <italic>IQR</italic> interquartile range</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Fig. 1</label><caption><p><bold>a</bold> ROC curve of the age of hysterectomy; <bold>b</bold> ROC curve of the age of pelvic masses resected; <bold>c</bold> ROC curve of the time interval from hysterectomy to the pelvic mass onset</p></caption><graphic xlink:href="13048_2019_504_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec8"><title>Results</title><sec id="Sec9"><title>Demographics data of study population</title><p id="Par15">Our study included 247 patients, of whom 80.16% (<italic>n</italic>&#x02009;=&#x02009;198) received simple hysterectomy, 5.67% (<italic>n</italic>&#x02009;=&#x02009;14) underwent hysterectomy with bilateral salpingectomy, 12.96% (<italic>n</italic>&#x02009;=&#x02009;32) hysterectomy with unilateral salpingo-oophorectomy, 1.21% (n&#x02009;=&#x02009;3) hysterectomy with bilateral salpingo-oophorectomy. In the group of simple hysterectomy, 166 cases (83.8%) performed total hysterectomy and 32 cases (16.2%) performed subtotal hysterectomy; while in the group of hysterectomy with simultaneous bilateral salpingectomy, all of the 14 cases were performed the procedure of total hysterectomy. The clinicopathological data of patients undergone simple hysterectomy or simultaneous bilateral salpingectomy was compared. Patients who undergone simple hysterectomy, 68.18% (<italic>n</italic>&#x02009;=&#x02009;135) of the pelvic massed were benign, and the remaining 31.82% (<italic>n</italic>&#x02009;=&#x02009;63) were malignant. In benign masses, ovarian origin accounted for 70.37%, oviduct origin 20.00%, encapsulated effusion 10.37%; in malignant masses, ovarian origin 76.19%, pelvic extraovarian malignancy 12.70%, peritoneal cancer 4.76%, gastrointestinal derived 4.76%. Patients who undergone hysterectomy with bilateral salpingectomy, 57.14% (<italic>n</italic>&#x02009;=&#x02009;8) were benign and 42.86% (n&#x02009;=&#x02009;6) were malignant. In benign masses, ovarian origin accounted for 37.50%, encapsulated effusion 50%, extraovarian benign mass 12.5%; in malignant group, ovarian origin 83.3%, and pelvic exogenous derived 16.7%.</p></sec><sec id="Sec10"><title>Clinical characteristics between two groups</title><p id="Par16">Univariate analysis showed that the age of surgery for pelvic mass in patients undergoing hysterectomy with simultaneous salpingectomy was significantly younger than those without salpingectomy [median(IQR), 44.5 (41.0, 49.0) years vs 50.0 (47.0, 56.0), <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001]. Grouped by ROC curve, more patients below 52&#x02009;years old with pelvic mass were found in salpingectomy group (100% vs 57.58%, <italic>P</italic>&#x02009;=&#x02009;0.001). The time interval from hysterectomy to the pelvic mass onset was significantly shorter (median, 2 vs 5&#x02009;years, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001) and more patients had the time interval less than 5&#x02009;years in salpingectomy group. Further statistics were performed separately referring to the time interval from hysterectomy to the onset of benign and malignant pelvic masses. Results revealed that the time interval between benign pelvic masses and hysterectomy was shorter in salpingectomy group [median(IQR), 1.5 (0.7,3.0) vs 4.0 (2, 9.25), <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001]. On the contrary, there was no difference between the two groups in the time interval between hysterectomy and malignant pelvic masses onset. In addition, the cause of hysterectomy being endometriosis or adenomyosis was significantly more common in the salpingectomy group (71.4% vs 24.2%, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001), while hysterectomy due to leiomyoma was less common (35.7% vs 67.7%, <italic>P</italic>&#x02009;=&#x02009;0.020). There were no significant differences in age of hysterectomy and the main complaints of pelvic mass (Table <xref rid="Tab1" ref-type="table">1</xref>). Multivariate analysis showed that there was no significant difference in the time interval from pelvic mass onset to the hysterectomy between two groups. Thus, in the salpingectomy group, the etiology for hysterectomy being endometriosis or adenomyosis may be related to the earlier onset of pelvic masses (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Multivariate analysis of clinical characteristics of pelvic mass after hysterectomy with or without bilateral salpingectomy</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Parameter</th><th>&#x003b2;</th><th>S.E.</th><th><italic>P</italic> value</th><th>OR(95%CI)</th></tr></thead><tbody><tr><td>Intercept</td><td>&#x02212;2.404</td><td>0.644</td><td>&#x0003c;.0001</td><td/></tr><tr><td>Endometriosis/adenomyosis</td><td>1.511</td><td>0.640</td><td>0.018</td><td>4.532 (1.293&#x02013;15.880)</td></tr><tr><td>Leiomyoma</td><td>&#x02212;0.777</td><td>0.651</td><td>0.206</td><td>0.460 (0.138&#x02013;1.535)</td></tr><tr><td>Age of resection of pelvic mass</td><td>&#x02212;1.523</td><td>0.832</td><td>0.067</td><td>0.218 (0.043&#x02013;1.114)</td></tr><tr><td>Time interval between hysterectomy and pelvic mass onset</td><td>&#x02212;0.237</td><td>0.741</td><td>0.750</td><td>0.789 (0.185&#x02013;3.373)</td></tr></tbody></table><table-wrap-foot><p>Notes: In multivariate analysis, the equation is of significance when the <italic>p</italic> value of the whole test less than 0.0001</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Pathology characteristics between two groups</title><p id="Par17">The pathology characteristics were compared in patients undergone hysterectomy with and without bilateral salpingectomy. Univariate analysis showed that the incidence of pelvic encapsulated effusion was higher in the salpingectomy group (28.6% vs 7.1%, <italic>P</italic>&#x02009;=&#x02009;0.021), while there was no significant difference between the two groups referring to other pathological types (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). However, when the main indications of hysterectomy (endometriosis/adenomyosis and leiomyoma) were included in analysis, multivariate analysis showed that there was no significant difference of the incidence of pelvic encapsulated effusion between the two groups (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). This may be explained by the previous history of endometriosis or adenomyosis in the salpingectomy group.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Univariate analysis of pathological characteristics of pelvic mass after hysterectomy with or without simultaneous bilateral salpingectomy</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Hys N(%)</th><th>Hys&#x02009;+&#x02009;BS N(%)</th><th><italic>P</italic> value</th></tr></thead><tbody><tr><td>Total number of cases</td><td>198</td><td>14</td><td/></tr><tr><td colspan="4">Malignant</td></tr><tr><td>&#x02003;No</td><td>135 (68.2)</td><td>8 (57.1)</td><td char="." align="char">0.391</td></tr><tr><td>&#x02003;Yes</td><td>63 (31.8)</td><td>6 (42.9)</td><td/></tr><tr><td colspan="4">&#x02003;Ovarian serous carcinoma</td></tr><tr><td>&#x02003;&#x02003;0</td><td>175 (88.4)</td><td>11 (78.57)</td><td char="." align="char">0.388</td></tr><tr><td>&#x02003;&#x02003;1</td><td>23 (11.6)</td><td>3 (21.43)</td><td/></tr><tr><td colspan="4">&#x02003;Ovarian mucous carcinoma</td></tr><tr><td>&#x02003;&#x02003;0</td><td>190 (96.0)</td><td>14 (100)</td><td char="." align="char">1.0</td></tr><tr><td>&#x02003;&#x02003;1</td><td>8 (4.0)</td><td>0 (0)</td><td/></tr><tr><td colspan="4">&#x02003;Ovarian endometrioid carcinoma</td></tr><tr><td>&#x02003;&#x02003;0</td><td>194 (98.0)</td><td>14 (100)</td><td char="." align="char">1.0</td></tr><tr><td>&#x02003;&#x02003;1</td><td>4 (2.0)</td><td>0 (0)</td><td/></tr><tr><td colspan="4">&#x02003;Ovarian clear cell carcinoma</td></tr><tr><td>&#x02003;&#x02003;0</td><td>195 (98.5)</td><td>13 (92.9)</td><td char="." align="char">0.241</td></tr><tr><td>&#x02003;&#x02003;1</td><td>3 (1.5)</td><td>1 (7.1)</td><td/></tr><tr><td colspan="4">&#x02003;Ovarian sarcoma</td></tr><tr><td>&#x02003;&#x02003;0</td><td>196 (99.0)</td><td>13 (92.9)</td><td char="." align="char">0.186</td></tr><tr><td>&#x02003;&#x02003;1</td><td>2 (1.0)</td><td>1 (7.1)</td><td/></tr><tr><td colspan="4">&#x02003;Ovarian undifferentiated carcinoma</td></tr><tr><td>&#x02003;&#x02003;0</td><td>196 (99.0)</td><td>14 (100)</td><td char="." align="char">1.0</td></tr><tr><td>&#x02003;&#x02003;1</td><td>2 (1.0)</td><td>0 (0)</td><td/></tr><tr><td colspan="4">&#x02003;Ovarian primary PNET</td></tr><tr><td>&#x02003;&#x02003;0</td><td>198 (100)</td><td>14 (100)</td><td char="." align="char">1.0</td></tr><tr><td>&#x02003;&#x02003;1</td><td>0 (0)</td><td>0 (0)</td><td/></tr><tr><td colspan="4">&#x02003;Other uncertain types of ovarian carcinoma</td></tr><tr><td>&#x02003;&#x02003;0</td><td>192 (96.97)</td><td>14 (100)</td><td char="." align="char">1.0</td></tr><tr><td>&#x02003;&#x02003;1</td><td>6 (3.0)</td><td>0 (0)</td><td/></tr><tr><td colspan="4">&#x02003;Pelvic extraovarian carcinoma</td></tr><tr><td>&#x02003;&#x02003;0</td><td>190 (96)</td><td>13 (92.9)</td><td char="." align="char">0.466</td></tr><tr><td>&#x02003;&#x02003;1</td><td>8 (4)</td><td>1 (7.1)</td><td/></tr><tr><td colspan="4">&#x02003;Peritoneal derived carcinoma</td></tr><tr><td>&#x02003;&#x02003;0</td><td>195 (98.5)</td><td>14 (100)</td><td char="." align="char">1.0</td></tr><tr><td>&#x02003;&#x02003;1</td><td>3 (1.5)</td><td>0 (0)</td><td/></tr><tr><td colspan="4">&#x02003;Vaginal stump carcinoma</td></tr><tr><td>&#x02003;&#x02003;0</td><td>197 (99.5)</td><td>14 (100)</td><td char="." align="char">1.0</td></tr><tr><td>&#x02003;&#x02003;1</td><td>1 (0.5)</td><td>0 (0)</td><td/></tr><tr><td colspan="4">&#x02003;Carcinoma in other sites</td></tr><tr><td>&#x02003;&#x02003;0</td><td>195 (98.5)</td><td>14 (100)</td><td char="." align="char">1.0</td></tr><tr><td>&#x02003;&#x02003;1</td><td>3 (1.5)</td><td>0 (0)</td><td/></tr><tr><td colspan="4">Benign</td></tr><tr><td>&#x02003;No</td><td>63 (31.8)</td><td>6 (42.9)</td><td char="." align="char">0.391</td></tr><tr><td>&#x02003;Yes</td><td>135 (68.2)</td><td>8 (57.1)</td><td/></tr><tr><td colspan="4">&#x02003;Cervical leiomyoma</td></tr><tr><td>&#x02003;&#x02003;0</td><td>194 (98.0)</td><td>14 (100)</td><td char="." align="char">1.0</td></tr><tr><td>&#x02003;&#x02003;1</td><td>4 (2.0)</td><td>0 (0)</td><td/></tr><tr><td colspan="4">&#x02003;Cervical intraepithelial neoplasia</td></tr><tr><td>&#x02003;&#x02003;0</td><td>197 (99.5)</td><td>14 (100)</td><td char="." align="char">1.0</td></tr><tr><td>&#x02003;&#x02003;1</td><td>1 (0.5)</td><td>0 (0)</td><td/></tr><tr><td colspan="4">&#x02003;Hydrosalpinx</td></tr><tr><td>&#x02003;&#x02003;0</td><td>178 (89.9)</td><td>14 (100)</td><td char="." align="char">0.371</td></tr><tr><td>&#x02003;&#x02003;1</td><td>20 (10.0)</td><td>0 (0)</td><td/></tr><tr><td colspan="4">&#x02003;Mesenchymal cyst of oviduct</td></tr><tr><td>&#x02003;&#x02003;0</td><td>191 (93.9)</td><td>14 (100)</td><td char="." align="char">1.0</td></tr><tr><td>&#x02003;&#x02003;1</td><td>7 (6.1)</td><td>0 (0)</td><td/></tr><tr><td colspan="4">&#x02003;Ovarian oviduct abscess</td></tr><tr><td>&#x02003;&#x02003;0</td><td>196 (99.0)</td><td>14 (100)</td><td char="." align="char">1.0</td></tr><tr><td>&#x02003;&#x02003;1</td><td>2 (1.0)</td><td>0 (0)</td><td/></tr><tr><td colspan="4">&#x02003;Ovarian endometriosis</td></tr><tr><td>&#x02003;&#x02003;0</td><td>168 (84.8)</td><td>12 (85.7)</td><td char="." align="char">1.0</td></tr><tr><td>&#x02003;&#x02003;1</td><td>30 (15.2)</td><td>2 (14.3)</td><td/></tr><tr><td colspan="4">&#x02003;Ovarian physiological cysts</td></tr><tr><td>&#x02003;&#x02003;0</td><td>178 (89.9)</td><td>14 (100)</td><td char="." align="char">1.0</td></tr><tr><td>&#x02003;&#x02003;1</td><td>20 (10.1)</td><td>0 (0)</td><td/></tr><tr><td colspan="4">&#x02003;Ovarian serous cystadenoma</td></tr><tr><td>&#x02003;&#x02003;0</td><td>184 (92.9)</td><td>13 (92.8)</td><td char="." align="char">1.0</td></tr><tr><td>&#x02003;&#x02003;1</td><td>14 (7.1)</td><td>1 (7.2)</td><td/></tr><tr><td colspan="4">&#x02003;Ovarian mucinous cystadenoma</td></tr><tr><td>&#x02003;&#x02003;0</td><td>178 (89.9)</td><td>14 (100)</td><td char="." align="char">0.370</td></tr><tr><td>&#x02003;&#x02003;1</td><td>20 (10.1)</td><td>0 (0)</td><td/></tr><tr><td colspan="4">&#x02003;Ovarian fibroma</td></tr><tr><td>&#x02003;&#x02003;0</td><td>194 (98.0)</td><td>14 (100)</td><td char="." align="char">1.0</td></tr><tr><td>&#x02003;&#x02003;1</td><td>4 (2.0)</td><td>0 (0)</td><td/></tr><tr><td colspan="4">&#x02003;Ovarian teratoma</td></tr><tr><td>&#x02003;&#x02003;0</td><td>195 (98.5)</td><td>14 (100)</td><td char="." align="char">1.0</td></tr><tr><td>&#x02003;&#x02003;1</td><td>3 (1.5)</td><td>0 (0)</td><td/></tr><tr><td colspan="4">&#x02003;Ovarian epidermoid cyst</td></tr><tr><td>&#x02003;&#x02003;0</td><td>196 (99.0)</td><td>14 (100)</td><td char="." align="char">1.0</td></tr><tr><td>&#x02003;&#x02003;1</td><td>2 (1.0)</td><td>0 (0)</td><td/></tr><tr><td colspan="4">&#x02003;Encapsulated effusion</td></tr><tr><td>&#x02003;&#x02003;0</td><td>184 (92.9)</td><td>10 (71.4)</td><td char="." align="char">0.021</td></tr><tr><td>&#x02003;&#x02003;1</td><td>14 (7.1)</td><td>4 (28.6)</td><td/></tr><tr><td colspan="4">&#x02003;Intravascular leiomyomatosis</td></tr><tr><td>&#x02003;&#x02003;0</td><td>196 (99.0)</td><td>13 (92.9)</td><td char="." align="char">0.186</td></tr><tr><td>&#x02003;&#x02003;1</td><td>2 (1.0)</td><td>1 (7.1)</td><td/></tr><tr><td colspan="4">&#x02003;Pelvic leiomyoma</td></tr><tr><td>&#x02003;&#x02003;0</td><td>196 (99.0)</td><td>14 (100)</td><td char="." align="char">1.0</td></tr><tr><td>&#x02003;&#x02003;1</td><td>2 (1.0)</td><td>0 (0)</td><td/></tr><tr><td colspan="4">&#x02003;Others benign masses arising from extraovarian sites</td></tr><tr><td>&#x02003;&#x02003;0</td><td>192 (97.0)</td><td>14 (100)</td><td char="." align="char">1.0</td></tr><tr><td>&#x02003;&#x02003;1</td><td>6 (3.0)</td><td>0 (0)</td><td/></tr></tbody></table><table-wrap-foot><p><italic>Abbreviations</italic>: <italic>BS</italic> bilateral salpingectomy, <italic>Hys</italic> Hysterectomy, <italic>IQR</italic> interquartile range, <italic>PNET</italic> primitive neuroectodermal tumor</p></table-wrap-foot></table-wrap><table-wrap id="Tab4"><label>Table 4</label><caption><p>Multivariate analysis of pathological characteristics of pelvic mass after hysterectomy with or without bilateral salpingectomy</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Parameter</th><th>&#x003b2;</th><th>S.E.</th><th>
<italic>P</italic>
</th><th>OR(95%CI)</th></tr></thead><tbody><tr><td>Intercept</td><td>&#x02212;3.260</td><td>0.649</td><td>&#x0003c;.0001</td><td/></tr><tr><td>Encapsulated effusion</td><td>0.970</td><td>0.697</td><td>0.164</td><td>2.639 (0.673&#x02013;10.351)</td></tr><tr><td>Endometriosis/adenomyosis</td><td>1.729</td><td>0.651</td><td>0.008</td><td>5.637 (1.574&#x02013;20.187)</td></tr><tr><td>Leiomyoma</td><td>&#x02212;0.713</td><td>0.629</td><td>0.257</td><td>0.490 (0.143&#x02013;1.683)</td></tr></tbody></table><table-wrap-foot><p>Notes: In multivariate analysis, the equation is of significance when the <italic>p</italic> value of the whole test less than 0.0001</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec12"><title>Discussion</title><p id="Par18">Hysterectomy is one of the most commonly used surgical methods for gynecological benign diseases. Patients always hope that they will not receive reoperation for gynecological diseases when hysterectomy was performed, which is not the case. The occurrence of pelvic masses after hysterectomy is one of the most common causes for reoperation. 39% of women who underwent hysterectomy for benign gynecologic indications received elective bilateral salpingo-oophorectomy to prevent ovarian cancer [<xref ref-type="bibr" rid="CR7">7</xref>]. Recent studies shown that prophylactic bilateral salpingectomy is helpful not only in preventing high-grade serous type ovarian cancer, but also in decreasing adnexal pathologies [<xref ref-type="bibr" rid="CR8">8</xref>]. Question was raised subsequently on whether or not the fallopian tubes are resected during hysterectomy relate to the nature and origin of the subsequent pelvic masses. However, there is no consensus on whether bilateral fallopian tubes should be resected with hysterectomy for benign diseases in premenopausal women.</p><p id="Par19">Total of 247 patients were enrolled in this study. In simple hysterectomy group, the most common chief complaints for the onset of pelvic mass were found by physical examination, abdominal distension and anorexia. Most common chief complaints in hysterectomy with salpingectomy group were found by physical examination and abdominal pain. 20.20% benign masses were derived from oviduct, and no malignant masses were derived from oviduct for the former group. Neither benign nor malignant masses were derived from oviduct in the latter group.</p><p id="Par20">It has been thought that the fallopian tube has little physiological function after completing fertility, and may have potential of inducing cancer. More and more evidences show that ovarian cancer, especially high-grade serous carcinoma, originates from the fallopian tube. Malignant transformation of the fallopian tube can lead not only to fallopian tubal carcinoma, but also lead to the occurrence of ovarian and peritoneal carcinoma [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Bilateral salpingectomy can reduce the risk of ovarian carcinoma for women with BRCA1/2 gene mutations or general population [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par21">In addition, the retained fallopian tubes have the risk of secondary benign lesions, such as hydrosalpinx, fallopian tube ovarian abscess, fallopian tube prolapse, mesenchymal cyst of oviduct, etc. [<xref ref-type="bibr" rid="CR13">13</xref>]. It has been reported that the risk of reoperation due to tubal diseases after hysterectomy without bilateral salpingectomy is twice as high as that with bilateral salpingectomy. Morse, et al. reported that women who underwent hysterectomy had 8% lifetime risk of reoperation for hydrosalpinx [<xref ref-type="bibr" rid="CR14">14</xref>]. Another retrospective study reported that patients without preventive salpingectomy had a higher incidence of adnexal benign tumors (26.9% vs 13.9%, <italic>P</italic>&#x02009;=&#x02009;0.02) [<xref ref-type="bibr" rid="CR15">15</xref>]. The percentage of simple hysterectomy and hysterectomy with bilateral salpingectomy in our study is similar to those of Shiber Linda Dalal, et al. (80.16, and 5.67% respectively in the former one; 76, and 4% respectively in the latter one,) [<xref ref-type="bibr" rid="CR16">16</xref>]. Shiber, et al. revealed that 82% of pelvic masses following hysterectomy are benign, and 18% were malignant. 12.4% were derived from fallopian tubes, accounting for 6.7% of benign masses and 12.9% of malignant masses. Therefore, the authors suggest that simultaneous salpingectomy with hysterectomy may reduce the incidence of benign tumors derived from the fallopian tubes. In this study, 68.2% of the pelvic masses in the simple hysterectomy group were benign and 31.8% were malignant. Tubular masses accounted for 16.2% of the total pelvic masses and 21.5% of the benign masses, and there were no malignant tumors. In the simultaneous salpingectomy group, 57.1% of the pelvic masses were benign and 42.9% were malignant with none of the masses derived from fallopian tube. Therefore, the results of this study are in accordance to the results of Shiber that hysterectomy combined with simultaneous bilateral salpingectomy may reduce the incidence of fallopian tubes derived pelvic masses, which accounted for 12.4&#x02013;16.2% of total pelvic masses and 6.7&#x02013;21.5% of total benign pelvic masses.</p><p id="Par22">Furthermore, we compared the clinicopathological data of patients who underwent hysterectomy with and without simultaneous bilateral salpingectomy in this study. After adjusting the factors of more patients with endometriosis or adenomyosis in salpingectomy group, we found that there was no statistical difference between two groups on the age of pelvic mass onset, time interval between twice operations, main complaints when pelvic mass was found, and proportion of benign and malignant tumors. We also found that salpingectomy lead to no difference on the malignant pelvic masses between two groups, but cause difference on the benign pelvic masses. On the one hand, there were fewer cases with salpingectomy in this study, which may affect the statistical results. On the other hand, the objects of this study were the patients who underwent reoperation due to pelvic mass after simple hysterectomy with and without simultaneous bilateral salpingectomy, and we did not enrolled all patients underwent hysterectomy. Therefore, result of this study cannot concluded that simultaneous salpingectomy cannot reduce the incidence of benign and malignant masses, and cannot make difference on the nature of the pelvic masses. The prospective study we are currently conducting may help explaining this issue.</p></sec><sec id="Sec13"><title>Conclusion</title><p id="Par23">In conclusion, the results of this study showed that 14.65% of the pelvic masses in the hysterectomy group originated from fallopian tubes, accounting for 21.48% of the benign masses, while the pelvic masses in the salpingectomy group had no tumors originating from fallopian tubes. Therefore, hysterectomy with simultaneous bilateral salpingectomy may reduce the recurrence of pelvic masses, especially benign pelvic masses. However, there were no significant differences in clinical features and pathological types between the two groups.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>IQR</term><def><p id="Par5">Interquartile range</p></def></def-item><def-item><term>ROC</term><def><p id="Par6">Receiver operating characteristic curve</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>We appreciate the gynecologists at Peking Union Medical College Hospital for their diligent clinical work and precise data recording about the cases we reported in this article.</p><sec id="FPar1"><title>Funding</title><p id="Par24">This study was funded by CAMS Youth Talent Award Project (No. 2018RC320006), CAMS Innovation Fund for Medical Sciences (CIFMS) (No. 2016-I2M-1-002), and Chinese Academy of Medical Sciences Initiative for Innovative Medicine (CAMS-2017-I2M-1-002).</p></sec><sec id="FPar2" sec-type="data-availability"><title>Availability of data and materials</title><p id="Par25">The dataset supporting the conclusions of this article is included within the article and its Additional files.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>HS, SW, and LZ developed the idea for the project. The study was designed by SW. XC, XW, and MJ executed the study and performed the data analysis and takes full responsibility for the integrity of the data. XC and XW drafted the manuscript with inputs and critical discussion from QF, JL, DS and JL. YX had reviewed the pathological slides. The final version has been approved by all authors.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p>This study was approved by the Ethics Committee of Peking Union Medical College Hospital on Aug. 2017 (No. S-K331).</p></sec><sec id="FPar4"><title>Consent for publication</title><p>Not applicable.</p></sec><sec id="FPar5"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brill</surname><given-names>AI</given-names></name><name><surname>Nezhat</surname><given-names>F</given-names></name><name><surname>Nezhat</surname><given-names>CH</given-names></name><etal/></person-group><article-title>The incidence of adhesions after prior laparotomy: a laparoscopic appraisal</article-title><source>Obstet Gynecol</source><year>1995</year><volume>85</volume><fpage>269</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1016/0029-7844(94)00352-E</pub-id><pub-id pub-id-type="pmid">7824244</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davey</surname><given-names>AK</given-names></name><name><surname>Maher</surname><given-names>PJ</given-names></name></person-group><article-title>Surgical adhesions: a timely update, a great challenge for the future</article-title><source>J Minim Invasive Gynecol</source><year>2007</year><volume>14</volume><fpage>15</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.jmig.2006.07.013</pub-id><pub-id pub-id-type="pmid">17218224</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diamond</surname><given-names>MP</given-names></name><name><surname>Wexner</surname><given-names>SD</given-names></name><name><surname>diZereg</surname><given-names>GS</given-names></name><etal/></person-group><article-title>Adhesion prevention and reduction: current status and future recommendations of a multinational interdisciplinary consensus conference</article-title><source>Surg Innov</source><year>2010</year><volume>12</volume><issue>3</issue><fpage>183</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1177/1553350610379869</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Committee on Gynecologic Practice</collab></person-group><article-title>Committee opinion no. 620: salpingectomy for ovarian cancer prevention</article-title><source>Obstet Gynecol</source><year>2015</year><volume>125</volume><issue>1</issue><fpage>279</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1097/01.AOG.0000459871.88564.09</pub-id><pub-id pub-id-type="pmid">25560145</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berlit</surname><given-names>S</given-names></name><name><surname>Tuschy</surname><given-names>B</given-names></name><name><surname>Kehl</surname><given-names>S</given-names></name><etal/></person-group><article-title>Laparoscopic supracervical hysterectomy with concomitant bilateral salpingectomy- why not?</article-title><source>Anticancer Res</source><year>2013</year><volume>33</volume><issue>6</issue><fpage>2771</fpage><lpage>2774</lpage><pub-id pub-id-type="pmid">23749939</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dietl</surname><given-names>J</given-names></name><name><surname>Wischhusen</surname><given-names>J</given-names></name><name><surname>Hausler</surname><given-names>SF</given-names></name></person-group><article-title>The post-reproductive fallopian tube: better removed?</article-title><source>Hum Reprod</source><year>2011</year><volume>26</volume><issue>11</issue><fpage>2918</fpage><lpage>2924</lpage><pub-id pub-id-type="doi">10.1093/humrep/der274</pub-id><pub-id pub-id-type="pmid">21849300</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asante</surname><given-names>A</given-names></name><name><surname>Whiteman</surname><given-names>MA</given-names></name><name><surname>Cox</surname><given-names>S</given-names></name><etal/></person-group><article-title>Elective oophorectomy in the United States: trends and in-hospital complications, 1998-2006</article-title><source>Obstet Gynecol</source><year>2010</year><volume>116</volume><issue>5</issue><fpage>1088</fpage><lpage>1095</lpage><pub-id pub-id-type="doi">10.1097/AOG.0b013e3181f5ec9d</pub-id><pub-id pub-id-type="pmid">20966693</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Dhakal S, Zheng YX, Yi XF. Current Updates on Salpingectomy for the Prevention of Ovarian Cancer and Its Practice Patterns Worldwide[J]. Chin Med Sci J. 2017;32(3):185&#x02013;192.</mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Falconer H, Yin L, Gronberg H, et al. Ovarian cancer risk after salpingectomy: a nationwide population-based study[J]. J Natl Cancer Inst. 2015;107(2).</mixed-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madsen</surname><given-names>C</given-names></name><name><surname>Baandrup</surname><given-names>L</given-names></name><name><surname>Dehlendorff</surname><given-names>C</given-names></name><etal/></person-group><article-title>Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: a nationwide case-control study</article-title><source>Obstet Gynecol Scand</source><year>2015</year><volume>94</volume><issue>1</issue><fpage>86</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1111/aogs.12516</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erickson</surname><given-names>BK</given-names></name><name><surname>Conner</surname><given-names>MG</given-names></name><name><surname>Landen</surname><given-names>CN</given-names><suffix>Jr</suffix></name></person-group><article-title>The role of the fallopian tube in the origin of ovarian cancer</article-title><source>Am J Obstet Gynecol</source><year>2013</year><volume>209</volume><fpage>409</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1016/j.ajog.2013.04.019</pub-id><pub-id pub-id-type="pmid">23583217</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kindelberger</surname><given-names>DW</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Miron</surname><given-names>A</given-names></name><etal/></person-group><article-title>Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship</article-title><source>Am J Surg Pathol</source><year>2007</year><volume>31</volume><issue>2</issue><fpage>161</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1097/01.pas.0000213335.40358.47</pub-id><pub-id pub-id-type="pmid">17255760</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghezzi</surname><given-names>F</given-names></name><name><surname>Cromi</surname><given-names>A</given-names></name><name><surname>Siesto</surname><given-names>G</given-names></name><etal/></person-group><article-title>Infectious morbidity after total laparoscopic hysterectomy: does concomitant salpingectomy make a difference?</article-title><source>BJOG Int J Obstet Gynaecol</source><year>2009</year><volume>116</volume><issue>4</issue><fpage>589</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1111/j.1471-0528.2008.02085.x</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morse</surname><given-names>AN</given-names></name><name><surname>Schroeder</surname><given-names>CB</given-names></name><name><surname>Magrina</surname><given-names>JF</given-names></name><etal/></person-group><article-title>The risk of hydrosalpinx formation and adnexectomy following tubal ligation and subsequent hysterectomy: a historical cohort study</article-title><source>Am J Obstet Gynecol</source><year>2006</year><volume>194</volume><fpage>1273</fpage><lpage>1276</lpage><pub-id pub-id-type="doi">10.1016/j.ajog.2005.11.014</pub-id><pub-id pub-id-type="pmid">16579950</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vorwergk</surname><given-names>J</given-names></name><name><surname>Radosa</surname><given-names>MP</given-names></name><name><surname>Nicolaus</surname><given-names>K</given-names></name><etal/></person-group><article-title>Prophylactic bilateral salpingectomy (PBS) to reduce ovarian cancer risk incorporated in standard premenopausal hysterectomy: complications and re-operation rate</article-title><source>J Cancer Res Clin Oncol</source><year>2014</year><volume>140</volume><issue>5</issue><fpage>855</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.1007/s00432-014-1622-6</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiber</surname><given-names>LD</given-names></name><name><surname>Gregory</surname><given-names>EJ</given-names></name><name><surname>Gaskins</surname><given-names>JT</given-names></name><etal/></person-group><article-title>Adnexal masses requiring reoperation in women with previous hysterectomy with or without adnexectomy</article-title><source>Eur J Obstet Gynecol Reprod Biol</source><year>2017</year><volume>200</volume><fpage>123</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/j.ejogrb.2016.02.043</pub-id></element-citation></ref></ref-list></back></article>